HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Given the plethora of HDAC inhibitors demonstrating promising but variable activity in CTCL, we anticipate that future clinical trials of HDAC inhibitors will incorporate detailed molecular analysis of the tumors to identify predictive biomarkers of response or resistance to individual agents or as a class to enable delivery of personalized therapy.